Latest news with #NYB
Yahoo
11-08-2025
- Business
- Yahoo
It's 'impossible' to replace US dollar as global reserve currency
The dollar (DX=F, has weakened as markets price in more Federal Reserve interest cuts through 2026. Jane Foley, Rabobank head of FX strategy, joins Market Catalysts to discuss risks to Fed independence, the dollar's global role, and how politics could shape the currency outlook. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts. What in your view is priced into the dollar trade at this point? Obviously, we've seen some weakness here. Um again is the assumption there that we're going to get multiple cuts this year and where is there room for maybe disruption of that view in the market? Well, you know that the market is essentially thinking that you know through into 2026 we will get further Fed easing and you know a lot of that has already been priced in. Um I think what is perhaps more interesting for forecasters but equally very difficult to forecast is whether or not there will be sort of more implications of perhaps partisanship within the US systems. We did of course see the head of the Bureau of Labor statistics um lose a job last week um and of course with the the the Fed rolls coming up for reappointment that that raises or already has raised the issue of of Fed independence. So whether or not that will feed into credibility, whether or not that will have an impact on the dollar as investor confidence gets affected we have to wait and see. Now that is not our base case but certainly it is worth you know watching and and debating whether or not that does come through and into more of a market factor in in 2026. Is there any real risk to the dollar status as a global reserve currency? Well, it's going to be impossible to to replace the dollar as as reserve currency. The the US capital markets are just so deep that that that they cannot be replicated. But, you know we heard from Lagarde head of the ECB in in May that you know she would probably want to chip away a little bit more at that. And and I think from the Chinese authorities well they've been chipping away for the last few years and and what I mean by that is that you know both of them will probably try and make more of their trade invoiced in their domestic currencies, not the dollar. And you know when we look at trade that is invoiced in a certain currency there is a rough correlation between those currencies, the invoicing currencies, and central bank reserves. So that the dollar is certainly um at risk of having its status eroded as it has been for the last 20 years. But of course the US Treasury will push back against that significantly and it's quite possible that they want to see stable coins as as a means of of trying to push back. So again very interesting next few years I think on on that front. Related Videos Investors are most bullish since Feb., BofA survey shows Market rebound, key CPI report: A look at this week's catalysts Paramount, Tesla, crypto stocks: Trending Tickers Stock futures higher, US–China trade, Nvidia & AMD: 3 Things Sign in to access your portfolio
Yahoo
01-08-2025
- Business
- Yahoo
What a weaker dollar means for inflation
The US dollar ( has fallen this year, and that can have big implications for inflation. RSM chief economist Joe Brusuelas talks about that connection and when the impact of tariffs may start to show in the US economy. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime. turning out to the dollar index, it's seen many swings we know amid economic uncertainty. Joe, you highlight what the moves in the currency mean for inflation? Walk us through that. All right. When you get a sustained 10% decline in the value of the dollar, typically, you should expect to see a 1/2 of 1% increase in inflation over the next 6 to 12 months. We clearly are at that point, even though we had a nice rebound. I think it was 3.3% for the month of July, strongest month for the greenback this year, but nevertheless, the policy mix out of the administration, all points towards a weaker dollar, and I think that's what we're going to get. Moreover, when you take a look at import prices, especially import prices ex petroleum, it tells the tale. We're going to see more inflation and a weaker dollar going forward. Does Trump want a strong dollar? I would think he does, and I think, well, I think like all politicians, he wants to have his cake and eat it, too. He doesn't want de-dollarization, clearly, but he wants a weaker dollar because A, it really tends to juice the tech sector, and B, it will provide relief to the beleaguered manufacturing sector that's been in an effective recession for the past couple of years. Is it too soon to say the kind of impact the softer dollars had during this earnings season, particularly what it's meant for the multinationals? It's way too early to jump on that bandwagon. I think we're really going to be talking in the fourth quarter earnings, and then next year. Moreover, a lot of those firms that he wants to help are actually having real problems with the tariff issue because, you know, 45% of everything we import goes into domestic manufacturing. So policies at a cross purposes, a good portion of the time this year, which is why that economy slowed to 1.2% growth in the first half of the year, and we think it's not going to do much better. Our forecast for this year is 1.1%. Can I ask you when we talk about these tariff policies? We've been talking about them all show. There's the near to intermediate impact, but how long do we have to wait to see what the long-term impact is? Meaning, do I have to wait till does it have to be August 2026, and Joe and Josh are back on set for me to really know, okay, it's really boosted manufacturing job. It's really opened up all these new markets for American business. It's really raised this much revenue. It's a little worse, actually. So as of midnight last night, on once we get to October 5th, we're going to have an effective 18.3% tariff. The real problem is we won't really understand what any of this means, not till October 5th, 2026, but more like October 5th, 2027. Why? Why do you say that, Joe? Because it takes so long to pass through the tariff costs. You know, there are four points along the chain. You've got your retail, you've got your consumers, you've got your importers, and you've got your exporters. At each point of the supply chain, you're going to see a bit of it absorbed, a bit of it eaten. When we went through this in 2018, for example, we didn't see the full price of the increase in the price of washing machines, dryers, and dishwashers caused by tariffs show up on consumers' balance sheets until about two years later. Turned out 90% of that cost was eaten entirely by consumers. So when we talk about whether where the cost falls falls on the value chain, and there was this big debate, maybe it's really the key debate inside the Fed. Tell me if I'm wrong, but this debate about whether the the the tariff induced inflation is one time or transitory persistent. Even if it's one time, it could go on for some time. Is that part of the point? Well, that's right, and that's why they've been counseling patients because you just don't know. Right now, for all of the noise, right? The tariff rate that's showing up, which is causing revenues to rise, right? And from the Trump administration's point of view, that's an absolutely good thing. It's about 8.85%. It's not 30, it's not 50, it's not 15. But as we get into mid-October, it'll be closer to 20 is my sense because we're still not done with Mexico, and we're still not done with China, and then USMCA has to be renegotiated next year. So this is going to be a variable target. It's going to be a moving target, but nevertheless, if you cause the average price of goods imported in the United States to rise by 18.3%, that's going to be eaten. And here's why we say that. There's a lot of talk that, well, foreign exporters are just eating the price. You know, they're going to engage in invoice pricing. If that was the case, import prices would be falling significantly. They're not. They're actually rising. So that's just not happening. So that means it's not the exporter, it's going to be the importer, the retail, or the consumer. Those points on the chain where those are going to be eaten. Joe, I can honestly say that given the news flow today, you were the perfect guy to be sitting in that chair. That's very kind of you to say. Thank you. Thank you, sir. Thank you so much, Joe.
Business Wire
10-05-2025
- Business
- Business Wire
Nanyang Biologics and Precisya Global Inc Announce Strategic Collaboration to Validate Natural Compounds Against Genetic Disease Markers
SINGAPORE & WILMINGTON, Del.--(BUSINESS WIRE)--Nanyang Biologics (NYB) and Precisya Global Inc (PGI) announce a strategic collaboration to leverage our technologies in validating potential therapeutic benefits of natural compounds against genetically identified risk factors and predispositions for chronic diseases. The partnership combines PGI's genomic big data analytics with NYB's natural compound libraries and AI capabilities. The collaboration will leverage DTIGN (Drug-Target Interaction Graph Neural Network), NYB's proprietary AI model that has demonstrated a 27.03% improvement in prediction accuracy over leading methods. DTIGN significantly enhances the identification of active compounds and shortens early-stage discovery timelines. This technology will be used to screen compounds as NYB continues to build one of the world's largest natural compound libraries, unlocking novel therapeutic opportunities with exceptional precision and speed. As a key contributor to this strategic partnership, Precisya Global Inc will utilize advanced genomic data analysis platforms and specialized genetic knowledge from 22+ Million Scientific Publications to identify disease-relevant biomarkers. The company will provide secure access to anonymized patient genomic data in compliance with privacy regulations, while offering expert bioinformatic analysis of correlations between natural compound responses and genetic variants. This joint initiative bridges the gap between genomic analysis and natural compound research, aiming to accelerate the discovery of nature-based treatments for genetic diseases through AI-driven matching and rigorous validation processes. This enables personalized nature-based treatments for individuals with genetic health conditions, offering better outcomes, fewer side effects, and more affordable options. "This collaboration represents a significant advancement in precision medicine," said Roland Ong, Founder and Chairman of Nanyang Biologics. "By combining our natural compound expertise and DTIGN technology with PGI's genomic capabilities, we aim to develop more targeted and effective treatments while significantly reducing the time and cost typically associated with drug discovery." The partnership includes comprehensive validation through in vitro and in vivo assays, supported by joint biobanks and patient samples. This integrated approach ensures robust validation of potential therapeutic compounds while maintaining high scientific standards. About Precisya Global Inc: Precisya Global Inc (PGI) is a leading deep health tech company with its genomic big data and unique algorithms that maps the genetic interference pattern across the whole body metabolic pathway, identifying the causative and associative factors of chronic disease expressions Through PGI state-of-the-art technology platform and comprehensive genomic database, PGI delivers precise, data-driven insights that enable personalized healthcare solutions and accelerate plant based compounds drug development processes. About Nanyang Biologics Nanyang Biologics (NYB) is a biotech company using AI and biological data to understand drug-target interactions in disease pathways. Through its AI platform and compound libraries, NYB identifies promising therapeutic molecules and optimizes them for effectiveness. Using advanced machine learning techniques, NYB accelerates the discovery of next-generation treatments for cancer and chronic diseases.
